Anbio Biotechnology Class A Ordinary Shares (NNNN)vsResMed Inc (RMD)
NNNN
Anbio Biotechnology Class A Ordinary Shares
$6.34
-2.61%
HEALTHCARE · Cap: $283.98M
RMD
ResMed Inc
$218.27
-0.60%
HEALTHCARE · Cap: $31.89B
Smart Verdict
WallStSmart Research — data-driven comparison
ResMed Inc generates 65282% more annual revenue ($5.65B vs $8.65M). NNNN leads profitability with a 74.1% profit margin vs 27.0%. RMD trades at a lower P/E of 21.2x. RMD earns a higher WallStSmart Score of 65/100 (C+).
NNNN
Buy51
out of 100
Grade: C-
RMD
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for NNNN.
Margin of Safety
-24.1%
Fair Value
$209.29
Current Price
$218.27
$8.98 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 74 of every $100 in revenue as profit
Strong operational efficiency at 59.1%
Revenue surging 73.9% year-over-year
Every $100 of equity generates 24 in profit
Strong operational efficiency at 30.9%
Safe zone — low bankruptcy risk
Every $100 of equity generates 23 in profit
Keeps 27 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Generating 1.6B in free cash flow
Areas to Watch
Trading at 9.2x book value
2.8% earnings growth
Smaller company, higher risk/reward
Premium valuation, high expectations priced in
2.4% earnings growth
Comparative Analysis Report
WallStSmart ResearchBull Case : NNNN
The strongest argument for NNNN centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 74.1% and operating margin at 59.1%. Revenue growth of 73.9% demonstrates continued momentum.
Bull Case : RMD
The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.0% and operating margin at 30.9%. PEG of 1.33 suggests the stock is reasonably priced for its growth.
Bear Case : NNNN
The primary concerns for NNNN are Price/Book, EPS Growth, Market Cap. A P/E of 43.1x leaves little room for execution misses.
Bear Case : RMD
The primary concerns for RMD are EPS Growth.
Key Dynamics to Monitor
NNNN profiles as a growth stock while RMD is a mature play — different risk/reward profiles.
NNNN is growing revenue faster at 73.9% — sustainability is the question.
Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
RMD scores higher overall (65/100 vs 51/100), backed by strong 27.0% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Anbio Biotechnology Class A Ordinary Shares
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. The company is headquartered in Frankfurt am Main, Germany.
ResMed Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?